Calliditas Therapeutics AB (publ)
CALTNASDAQHealthcare
$40.00
$-0.04(-0.10%)
Market Cap$2.1B
P/E Ratio—
52W High$43.0
52W Low$15.25
Calliditas Therapeutics AB (publ) (CALT) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
CALT · earnings · updated Jun 8, 2026
Latest Earnings
Q4 FY2024Report Date: Nov 11, 2024EPS Actual
-$0.58
Est. -$0.22 · -163.6%
Revenue
—
Est. $0.01B
Fiscal Period
Q4 FY2024
FY ends December
Report Date
Nov 11, 2024
After Market Close
▼ Miss EPS
CALT reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.09
Rev. $41.31B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.09
Rev. Est.$41.31B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ▼ Q4 FY2024 | Nov 11, 2024 | -$0.22 | -$0.58 | -163.6% | — | $0.01B | — |
| ▼ Q3 FY2024 | Aug 13, 2024 | -$0.10 | -$0.16 | -60.0% | $0.05B | $0.00B | +1178.9% |
| ▼ Q2 FY2024 | May 23, 2024 | -$0.14 | -$0.88 | -528.6% | $0.03B | $0.03B | -10.8% |
| ▲ Q1 FY2024 | Mar 13, 2024 | -$0.07 | -$0.06 | +14.3% | $0.04B | — | — |
| ▼ Q4 FY2023 | Nov 7, 2023 | -$0.31 | -$0.58 | -87.1% | $0.03B | $0.03B | -9.8% |
| ▼ Q3 FY2023 | Aug 17, 2023 | -$0.17 | -$0.32 | -88.2% | $0.02B | $0.03B | -8.2% |
| ▼ Q2 FY2023 | May 16, 2023 | -$0.38 | -$0.67 | -76.3% | $0.02B | $0.02B | -17.3% |
| — Q2 FY2023 | Apr 26, 2023 | — | -$0.01 | — | $0.04B | — | — |
Q4 FY2024
Nov 11, 2024Miss
EPS Actual
-$0.58
EPS Est.
-$0.22
EPS Surpr.
-163.6%
Revenue
—
Q3 FY2024
Aug 13, 2024Miss
EPS Actual
-$0.16
EPS Est.
-$0.10
EPS Surpr.
-60.0%
Revenue
$0.05B
Q2 FY2024
May 23, 2024Miss
EPS Actual
-$0.88
EPS Est.
-$0.14
EPS Surpr.
-528.6%
Revenue
$0.03B
Q1 FY2024
Mar 13, 2024Beat
EPS Actual
-$0.06
EPS Est.
-$0.07
EPS Surpr.
+14.3%
Revenue
$0.04B
Q4 FY2023
Nov 7, 2023Miss
EPS Actual
-$0.58
EPS Est.
-$0.31
EPS Surpr.
-87.1%
Revenue
$0.03B
Q3 FY2023
Aug 17, 2023Miss
EPS Actual
-$0.32
EPS Est.
-$0.17
EPS Surpr.
-88.2%
Revenue
$0.02B
Q2 FY2023
May 16, 2023Miss
EPS Actual
-$0.67
EPS Est.
-$0.38
EPS Surpr.
-76.3%
Revenue
$0.02B
Q2 FY2023
Apr 26, 2023
EPS Actual
-$0.01
EPS Est.
—
EPS Surpr.
—
Revenue
$0.04B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2025 | $4.22 | $4.22 | $4.22 | 1 |
| Q3 FY2025 | $4.10 | $4.10 | $4.10 | 1 |
| Q2 FY2025 | $3.83 | $3.83 | $3.83 | 1 |
| Q1 FY2025 | $3.33 | $3.33 | $3.33 | 1 |
| Q4 FY2024 | $-1.52 | $4.55 | $9.09 | 2 |
| Q3 FY2024 | $-1.18 | $1.47 | $3.53 | 2 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2025 | $0.8B | $0.8B | $0.8B | 1 |
| Q3 FY2025 | $0.7B | $0.7B | $0.7B | 1 |
| Q2 FY2025 | $0.7B | $0.7B | $0.7B | 1 |
| Q1 FY2025 | $0.6B | $0.6B | $0.6B | 1 |
| Q4 FY2024 | $0.7B | $0.7B | $0.8B | 3 |
| Q3 FY2024 | $0.5B | $0.6B | $0.6B | 3 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q4 FY2024 | Nov 11, 2024 | -163.6% | $40.00 | — | — |
| ▼ Q3 FY2024 | Aug 13, 2024 | -60.0% | $39.18 | $39.24 | +0.15% |
| ▼ Q2 FY2024 | May 23, 2024 | -528.6% | $21.71 | $22.75 | +4.79% |
| ▲ Q1 FY2024 | Mar 13, 2024 | +14.3% | $22.07 | $23.18 | +5.03% |
| ▼ Q4 FY2023 | Nov 7, 2023 | -87.1% | $16.41 | $15.89 | -3.17% |
| ▼ Q3 FY2023 | Aug 17, 2023 | -88.2% | $18.95 | $15.90 | -16.09% |
| ▼ Q2 FY2023 | May 16, 2023 | -76.3% | $25.50 | $21.17 | -16.98% |
| — Q2 FY2023 | Apr 26, 2023 | — | $25.36 | $24.36 | -3.94% |
Q4 FY2024—
Report Date
Nov 11, 2024
EPS Beat/Miss
-163.6%
Price Before
$40.00
Price After
—
Q3 FY2024+0.15%
Report Date
Aug 13, 2024
EPS Beat/Miss
-60.0%
Price Before
$39.18
Price After
$39.24
Q2 FY2024+4.79%
Report Date
May 23, 2024
EPS Beat/Miss
-528.6%
Price Before
$21.71
Price After
$22.75
Q1 FY2024+5.03%
Report Date
Mar 13, 2024
EPS Beat/Miss
+14.3%
Price Before
$22.07
Price After
$23.18
Q4 FY2023-3.17%
Report Date
Nov 7, 2023
EPS Beat/Miss
-87.1%
Price Before
$16.41
Price After
$15.89
Q3 FY2023-16.09%
Report Date
Aug 17, 2023
EPS Beat/Miss
-88.2%
Price Before
$18.95
Price After
$15.90
Q2 FY2023-16.98%
Report Date
May 16, 2023
EPS Beat/Miss
-76.3%
Price Before
$25.50
Price After
$21.17
Q2 FY2023-3.94%
Report Date
Apr 26, 2023
EPS Beat/Miss
—
Price Before
$25.36
Price After
$24.36
Avg Beat Reaction+5.03%
Avg Miss Reaction-6.26%
Beat Rate1 / 8 quarters
Largest Move-16.98% (Q2 FY2023)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: CALT ends December
Calliditas Therapeutics AB (publ) (CALT) most recently reported earnings on November 11, 2024 for Q4 FY2024, posting EPS of $-0.58 — missing the analyst consensus of $-0.22 by -163.6%. The next CALT earnings date is expected around September 1, 2026.
Each quarter, investors track CALT earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. CALT revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
CALT's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
CALT earnings · 5 questionsCalliditas Therapeutics AB (publ)'s next earnings report is expected around September 1, 2026. CALT typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; CALT historically reports after market close (AMC).
CALT earnings datewhen is CALT earningsCALT next earnings datewhen does CALT report earningsCALT earnings calendar
▸ Source: FMP · Calliditas Therapeutics AB (publ) SEC filings · US GAAP · Calliditas Therapeutics AB (publ) SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026